Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

US government to provide $1.2 billion for development of AstraZeneca COVID-19 vaccine

by Michael McCoy
May 21, 2020 | A version of this story appeared in Volume 98, Issue 20

 

The US Biomedical Advanced Research and Development Authority will provide up to $1.2 billion to AstraZeneca to accelerate work on an adenoviral vector vaccine for COVID-19 that the UK drug firm licensed from the University of Oxford. The UK government is providing about $80 million to the effort. AstraZeneca says it has finalized agreements for at least 400 million doses of the vaccine, AZD1222, and has secured production capacity for 1 billion doses. Deliveries could begin in September under a fair allocation program the firm is developing.

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.